Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...

The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

Please provide your email address to receive an email when new articles are posted on . Pyzchiva, an ustekinumab biosimilar, is approved for all indications of the reference medicine, including ...

Funding a head-to-head study against a rival is risky. When that rival’s initials are “J” and “J,” it’s an even riskier bet. However, it’s just the sort of endeavor that appears to have paid off for ...

(RTTNews) - Sandoz Group AG (SDZNY.OB), a Swiss company that focuses on generic pharmaceuticals and biosimilars, today announced the approval of Pyzchiva. The FDA has granted approval to Pyzchiva, a ...